How much does Mind Medicine (mindmed) stock cost?
One share of MMEDF stock can currently be purchased for approximately $1.25. How many employees does Mind Medicine (MindMed) have? Mind Medicine (MindMed) employs 22 workers across the globe.
What are analysts'forecasts for Mind Medicine (mindmed)?
Their forecasts range from $2.00 to $2.00. On average, they expect Mind Medicine (MindMed)'s share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 36.3%. View analysts' price targets for Mind Medicine (MindMed) or view top-rated stocks among Wall Street analysts.
What is the PE (price earnings) ratio of Mind Medicine (mindmed)?
The P/E ratio of Mind Medicine (MindMed) is -8.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Is Mind Medicine (MindMed) a buy right now?
What is the official website for mindmed?
The official website for Mind Medicine (MindMed) is www.mindmed.co. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Is MindMed a buy or sell?
Mind Medicine (MindMed) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Why is MNMD stock going down?
Summary. The recent decline in MindMed's share price is a result of changes to the broader macroeconomic landscape. The FDA just approved MindMed's IND application, inducing a spike in the company's shares. Still, MindMed is down 67% in the past year.
Is MNMD shorted?
Short Shares Availability This table shows the number of shares of US:MNMD available to be shorted at a leading prime brokerage.
How many shares of MNMD are there?
422.44 million sharesShare Statistics MNMD has 422.44 million shares outstanding.
Is MindMed a good long term stock?
Mind Medicine (MindMed) Inc (MNMD) stock is down -53.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver's proprietary ranking system, gives MNMD stock a score of 31 out of a possible 100. That rank is influenced by a long-term technical score of 6.
Will MindMed go up?
On average, analysts give MNMD a Strong Buy rating. The average price target is $8, which means analysts expect the stock to gain by 633.94% over the next twelve months. That average ranking earns MNMD an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
What sector is Mnmd in?
stage biopharmaceutical companyDescription. Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.
What happened MindMed stock?
As MindMed's (NASDAQ: MNMD, NEO: MMED) stock has tumbled over the past year —the company is down an astonishing 82% since June 2021— fear of a Nasdaq delisting among retail investors has spread like wildfire.
What is Mmedf?
MMEDF – A clinical-stage psychedelic medicine biotech company, Mind Medicine Inc. (MMEDF), has benefited from growing demand for therapies for people with mental disorders.
Should I hold MNMD stock?
Subordinate holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
What happened MindMed stock?
As MindMed's (NASDAQ: MNMD, NEO: MMED) stock has tumbled over the past year —the company is down an astonishing 82% since June 2021— fear of a Nasdaq delisting among retail investors has spread like wildfire.
Should I invest in Mmed?
MNMD is an emerging player in the psychedelic drug space, but it still has a long way to go. Its EPS is expected to remain negative in its fiscal years 2021 and 2022 because its drugs are still in their early development stage. So, we think it's wise to avoid the stock now.
When did MNMD go public?
April 27th, 2021On Tuesday, April 27th, 2021, the MindMed stock started trading on the Nasdaq Capital Market. On the Nasdaq, the stock trades under the ticker symbol MNMD.
Should I buy or sell Mind Medicine (MindMed) stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last year. There are curr...
What is Mind Medicine (MindMed)'s stock price forecast for 2022?
3 analysts have issued 12 month price targets for Mind Medicine (MindMed)'s stock. Their forecasts range from 6.00 to 10.00. On average, they antic...
How has Mind Medicine (MindMed)'s stock price performed in 2022?
Mind Medicine (MindMed)'s stock was trading at 1.38 at the beginning of 2022. Since then, MNMD shares have decreased by 42.0% and is now trading at...
How were Mind Medicine (MindMed)'s earnings last quarter?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) issued its quarterly earnings data on Monday, March, 28th. The company reported ($0.04) earnings per sha...
Who are Mind Medicine (MindMed)'s key executives?
Mind Medicine (MindMed)'s management team includes the following people: Mr. Robert Barrow , CEO & Director (Age 33, Pay $708.41k) Dr. Miriam Ha...
Who are some of Mind Medicine (MindMed)'s key competitors?
Some companies that are related to Mind Medicine (MindMed) include USANA Health Sciences (USNA) , Cronos Group (CRON) , Cresco Labs (CRLBF) , T...
What is Mind Medicine (MindMed)'s stock symbol?
Mind Medicine (MindMed) trades on the NASDAQ under the ticker symbol "MNMD."
Who are Mind Medicine (MindMed)'s major shareholders?
Mind Medicine (MindMed)'s stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.9...
Which major investors are selling Mind Medicine (MindMed) stock?
MNMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Simplex Trading LLC...